Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with 3mg/kg BW Ipilimumab (Yervoy(R)) every 3 weeks for 12 weeks versus observation

Trial Profile

Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with 3mg/kg BW Ipilimumab (Yervoy(R)) every 3 weeks for 12 weeks versus observation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ADMEC
  • Most Recent Events

    • 28 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top